Guidance Sheet 8:
Safety and non-compliances

Any staff member can report safety events or non-compliances at any time during the trial. For information on withdrawal and unblinding, please see **Guidance Sheet 11: Withdrawal & Unblinding**.

OVERVIEW

- Safety data will be recorded during administration of the IMP and up to 36 weeks post-menstrual age
- ANYONE can report ANY events at ANY TIME
- Events should be reported as follows:
    - **Adverse Events or Reactions (AEs)**

      - Non-serious adverse events will not be routinely recorded. Adverse events which are part of the safety outcomes of this trial will be recorded in the case report form (CRF), where appropriate.
    - **Adverse reactions (AR)**

      - Adverse reactions (those with a suspected causal relationship to azithromycin) will be recorded on the Adverse Reactions CRF
    - **Serious Adverse Events or Reactions (SAE)**

      - Foreseeable serious adverse events (listed in the protocol) should not be reported as SAEs. Unforeseeable serious adverse events should be reported to the CTR as SAEs. The protocol contains a full list of foreseeable SAEs.
    - **Serious Adverse Reactions (SAR)**

      - SARs (SAEs which are related to the IMP) should be reported in the same manner as unforeseeable SAEs

CAUSALITY

- The casual relationship of each adverse event to the trial medication must be determined by a medically qualified individual
- This individual must be delegated this duty on the study delegation log
- Causality assessment cannot be downgraded by others

Guidance Sheet 8:
Safety and non-compliances

AZTEC
Azithromycin Therapy for Chronic Lung Disease
CARDIFF UNIVERSITY
PRIFYSGOL CAERDYDD
Centre for Trials Research
Canolfan Ymchwil Treialon

REPORTING

- Foreseeable Serious Adverse Events
  - The foreseeable adverse events listed in the protocol do not require immediate reporting as SAEs to the CTR or the CI. Only if these events are thought to be causally related to the IMP (SARs) would they require immediate reporting to the CTR.



- Unforeseeable Serious Adverse Events and adverse reactions
  - SAEs not on the list of foreseeable SAEs, and SARs must be reported to CTR immediately, but at least within 24 hours of the research site becoming aware of the event

Guidance Sheet 8:
Safety and non-compliances

AZTEC
Azithromycin Therapy for Chronic Lung Disease
CARDIFF UNIVERSITY
PRIFYSGOL CAERDYDD
Centre for Trials Research
Canolfan Ymchwil Treialon

- A paper SAE form will be completed (located in the document box) and faxed/emailed to CTR (Fax: 020 3043 2376 Email: CTR-Safety@Cardiff.ac.uk) and the original filed in the ISF
- Site staff may report an SAE immediately to the CTR by telephone, but this must be followed up with a SAE report form as soon as possible and within 24 hours of the site becoming aware of the event to the CTR
- The outcome of events "Resolving" or "Not Resolved" must be followed up until the status of the SAE changes
- CTR will review the report, request additional information and ensure assessment by the CI/delegate
- The CI will inform all PIs of relevant information that could adversely affect the safety of the participants

List of AZTEC foreseeable Serious Adverse Events	
Anaemia requiring blood transfusion+ • Anaemia requiring blood transfusion+ • Intracranial abnormality (haemorrhage or focal white matter damage) on cranial ultrasound scan or other imaging • Chronic lung disease of prematurity (or bronchopulmonary dysplasia) • Coagulopathy requiring treatment+ • Culture-proven infection or sepsis • Death (unless unforeseeable in this population) • Fluid retention • Fractures • Gastrointestinal bleeding • Haematuria • Hydrocephalus • Hyperbilirubinemia necessitating phototherapy and/or exchange transfusion+ • Hypercalcemia • Hypocalcaemia • Hyperglycaemia • Hypoglycaemia	• Hypertension • Hypotension treated with inotropes+ • Impaired renal function (urine output <0.5 ml/kg/hour and/or serum creatinine defined as >100 µmol/L) • Left ventricular hypertrophy on echocardiography • Low serum sodium level/hyponatremia (defined as sodium <130 mmol/L) • Liver failure, clinically significant • Necrotising enterocolitis or gastrointestinal perforation • Neutropenia (defined as $<1x10_9$/L) • Patent ductus arteriosus (PDA) • Pneumothorax requiring treatment • Pulmonary haemorrhage, significant • Pulmonary hypertension requiring treatment with pulmonary vasodilator+ • Respiratory failure • Retinopathy of prematurity • Seizures requiring treatment+ • Thrombocytopenia
Events marked with + that do not require treatment will not be deemed serious	

Guidance Sheet 8:
Safety and non-compliances

AZTEC
Azithromycin Therapy for Chronic Lung Disease
CARDIFF UNIVERSITY
PRIFYSGOL CAERDYDD
Centre for Trials Research
Canolfan Ymchwil Treialon

Non-compliances: protocol deviations and serious breaches

- Any member of the study team can report incidents or protocol deviations
- Any incidents or deviations from the protocol, trial procedures, GCP, or regulatory requirements will need to be reported as soon as site staff become aware of the incident. Please email AZTEC@Cardiff.ac.uk, or call 029 2068 7990.
- Incidents relating to a dosing error should be notified to the CRF using a **Dosing Error Form**. Dosing error forms should be faxed/emailed to CTR immediately with any accompanying information (Fax: 020 3043 2376; Email: CTR-Safety@Cardiff.ac.uk)
- The original dosing error/non-compliance forms should be kept in the ISF
- CTR staff will review the report and assess whether the incident should be considered a deviation, violation, or potential serious breach, and to agree in collaboration with the site any corrective and protective actions to be implemented